Schizophrenia Medications Compared: Oral, Long-Acting Injectables, Clozapine and Cobenfy

Most people with schizophrenia start on an oral antipsychotic, and the choice among them turns more on side effects than on effectiveness: a large network meta-analysis of 32 oral antipsychotics found that efficacy differences between drugs are mostly gradual, while differences in side effects are more marked. Long-acting injectables (LAIs) deliver the same medicines every few weeks or months, clozapine is the established option when other antipsychotics have not worked, and xanomeline-trospium (Cobenfy), FDA-approved in September 2024, is the first antipsychotic for schizophrenia that targets cholinergic rather than dopamine receptors.

The American Psychiatric Association recommends antipsychotic treatment with monitoring for effectiveness and side effects, clozapine for treatment-resistant schizophrenia or substantial suicide risk, and long-acting injectables for people who prefer them. Every choice below is made with a prescriber who knows the person's history.

The four options at a glance

Oral antipsychotics: choosing by side-effect profile

The 2019 network meta-analysis pooled 402 trials with more than 53,000 participants. Almost all antipsychotics reduced overall symptoms more than placebo, but they differed widely in sedation, weight gain, prolactin elevation and effects on heart rhythm (QTc). Its authors concluded that clinicians should weigh each outcome according to the patient's medical problems and preferences.

In practice, that means the conversation is often about which side effects matter most to you:

• Weight, blood sugar and cholesterol. Second-generation antipsychotics as a class are associated with metabolic changes, including high blood sugar, abnormal lipids and weight gain, which can raise cardiovascular risk. Some agents carry much more of this risk than others.
• Movement side effects. Restlessness (akathisia), stiffness and tremor are more common with some drugs. Tardive dyskinesia, a potentially irreversible movement disorder, can develop with antipsychotic treatment, and its risk appears to increase with duration and cumulative dose.
• Prolactin. Some drugs raise the hormone prolactin far more than others; ask your prescriber what that could mean for you and how it would be checked.
• Sedation and heart rhythm, which matter for work, driving and people with cardiac risk.

The clozapine and injectable antipsychotic labels reviewed for this guide carry a Boxed Warning about increased mortality in elderly patients with dementia-related psychosis; that warning concerns a different population but often surprises people reading a label. The APA guideline also recommends continuing antipsychotic medication once symptoms have improved, so tolerability over years, not weeks, should drive the choice. Never stop an antipsychotic on your own; changes should be planned with the prescriber.

Long-acting injectables

LAIs are the same molecules given by injection at intervals. Examples include monthly paliperidone palmitate (Invega Sustenna) and monthly aripiprazole (Abilify Maintena). For people who have never taken the drug, the labels call for establishing tolerability with the oral form first.

The evidence for relapse prevention is consistent. A 2021 meta-analysis of 137 studies covering about 397,000 patients found LAIs associated with a lower risk of hospitalization or relapse than oral antipsychotics in randomized trials, cohort studies and pre-post studies alike. In a Finnish nationwide cohort followed for up to 20 years, clozapine and LAIs were associated with the lowest risk of rehospitalization in both chronic and first-episode patients. Observational studies can be biased, but the direction is the same across designs.

Not every LAI is alike. Olanzapine pamoate (Zyprexa Relprevv) carries a Boxed Warning for post-injection delirium and sedation syndrome: patients must be observed for at least 3 hours after each injection in a certified health care setting, and the drug is available only through a restricted program.

The APA guideline suggests an LAI when a person prefers it or has a history of poor or uncertain adherence. Some people value not having to remember daily pills; others dislike injections or the clinic visits. Both preferences are legitimate and worth stating to the prescriber.

Clozapine for treatment resistance

Clozapine is FDA-approved for severely ill patients with schizophrenia who have not responded adequately to standard antipsychotic treatment, and for reducing the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder. In the network meta-analysis it showed the largest average reduction in overall symptoms of the 32 drugs.

Its risks are serious and well defined. The label's Boxed Warning covers severe neutropenia, orthostatic hypotension with slow heart rate and fainting, seizures, myocarditis, pericarditis and cardiomyopathy, and increased mortality in elderly patients with dementia-related psychosis. It also warns about gastrointestinal hypomotility, which can range from constipation to bowel obstruction, and advises close monitoring and prompt treatment if constipation is identified.

What changed in 2025: the REMS is gone, the blood tests are not

For years, clozapine could only be prescribed and dispensed through a federal Risk Evaluation and Mitigation Strategy (REMS) that required enrolling patients and reporting blood counts. FDA removed that REMS effective June 13, 2025. Prescribers and pharmacies no longer need to enroll, and pharmacists no longer need to verify blood test results before dispensing. FDA still advises prescribers to monitor absolute neutrophil count (ANC) according to the prescribing information.

The schedule changes if counts drop, and the label has separate thresholds for people with benign ethnic neutropenia (Duffy-null associated neutrophil count). Removal of the REMS should make clozapine easier to access, but it does not make it a casual choice. Families of someone who has not improved after adequate trials of other antipsychotics can reasonably ask whether clozapine has been considered; a second opinion on psychiatric medication is one route.

Xanomeline-trospium (Cobenfy): what is new and what is not yet known

FDA approved Cobenfy on September 26, 2024, for schizophrenia in adults, describing it as the first antipsychotic for schizophrenia that targets cholinergic receptors rather than dopamine receptors. It combines xanomeline, a muscarinic agonist, with trospium chloride, a muscarinic antagonist. Approval rested on two 5-week placebo-controlled trials.

Its side effects differ from dopamine-blocking drugs. The most common were nausea, indigestion, constipation, vomiting, high blood pressure, abdominal pain, diarrhea, fast heart rate, dizziness and reflux. The label contraindicates it in urinary retention, moderate or severe liver impairment, gastric retention and untreated narrow-angle glaucoma; it is not recommended in mild liver impairment or moderate to severe kidney impairment, and liver tests and heart rate are checked before starting. It is taken on an empty stomach, twice daily, with timing and dose set by the prescriber.

What the evidence does not show yet: the pivotal trials lasted 5 weeks, and the efficacy data in its label come from 2 placebo-controlled trials rather than head-to-head comparisons with established antipsychotics. As an add-on to existing antipsychotics, the phase 3 ARISE trial did not reach statistical significance on its primary endpoint, according to topline results Bristol Myers Squibb announced on April 22, 2025. The label's indication is schizophrenia in adults, and its efficacy data come from trials of Cobenfy on its own, so the current evidence does not establish a benefit from adding it to another antipsychotic.

When a medication seems not to be working

Before concluding that a drug has failed, prescribers usually check a short list of common explanations. Working through it together avoids abandoning a medicine that could help, or staying too long on one that will not.

• Is it actually being taken? Missed doses are common with any daily medicine and are not a moral failing. Pill organizers, phone reminders, a family member's support or a long-acting injectable can all help.
• Has the trial been long enough, at a dose the prescriber considers adequate? Some improvement can take weeks, and the prescriber judges what "adequate" means for each drug.
• Is something else interfering? Cannabis and other drugs, heavy alcohol use, poor sleep and major stress can all worsen symptoms. Smoking also matters: tobacco smoke lowers clozapine levels, and the label advises considering a dose reduction when someone stops smoking, so tell the prescriber if you start or stop.
• Are side effects the real problem? Restlessness, sedation or weight gain often lead people to skip doses quietly. Saying so openly gives the prescriber a chance to fix it.
• Is the diagnosis right? Mood disorders with psychotic features, substance-induced psychosis and medical causes call for different plans.

Switching from one antipsychotic to another is usually done gradually under the prescriber's direction, sometimes overlapping the two for a period. Do not attempt a switch, or stop a medicine because you feel well, without that plan.

Medication is one part of treatment

The APA guideline pairs medication with psychosocial treatment: cognitive-behavioral therapy for psychosis, psychoeducation, supported employment services and, for a first episode, a coordinated specialty care program. These approaches help people understand their illness, recognize early warning signs of relapse, cope with persistent symptoms and return to school or work. Family involvement, with the person's permission, often makes it easier to notice changes early and keep treatment on track.

A practical example, offered as an illustration rather than a real patient: a young man has done well on an oral antipsychotic but has twice stopped it after feeling better, each time followed by a relapse. He dislikes daily pills and has gained weight. With his prescriber he discusses switching to a long-acting injectable of a medicine with a lower metabolic burden, after confirming he tolerates the oral form, while adding nutrition support and therapy focused on relapse warning signs. If the illness had instead persisted despite adequate trials of at least two different antipsychotics, the conversation would have turned to clozapine.

Monitoring that every option needs

The guide to antipsychotic metabolic monitoring lays out a schedule, and lifestyle support (sleep, nutrition, physical activity) is part of reducing metabolic risk. Cost and coverage can affect which drug is practical; see prior authorization for psychiatric medications and generic versus brand-name medications.

How the choice is usually made

1. Confirm the diagnosis and rule out medical and substance causes, especially in a first episode (see what families should do after a first episode of psychosis).
2. Choose an oral antipsychotic whose side-effect profile fits the person's health, priorities and past responses.
3. Give it an adequate trial at an adequate dose, confirming it is actually being taken.
4. If adherence is uncertain or the person prefers it, consider an LAI.
5. If adequate trials of at least two different antipsychotics have not worked, or suicidal behavior recurs, discuss clozapine.
6. Consider Cobenfy when its mechanism and side-effect profile suit the person, keeping its shorter evidence base in mind.

Pregnancy, breastfeeding, heart disease, diabetes and substance use all change the calculation; the guide to psychiatric medications during pregnancy covers one of these. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Questions to ask the prescriber

• Which side effects are you most concerned about for me, and how will we check for them?
• How long should we try this medication before judging it?
• Would a long-acting injectable make sense for me, and which one?
• Have I had enough adequate trials that clozapine should be discussed?
• Is Cobenfy an option given my liver, kidney, bladder and eye health?
• Who orders and reviews my blood tests, and how will I get the results?

How Dr. Lewis's practice fits

The practice's prescribers provide psychiatric evaluation and medication management, alongside psychotherapy, lab testing, and nutrition and lifestyle psychiatry. For background, see the site's pages on severe mental illness beyond mood disorders and medication management. Whether the team treats schizophrenia, or can provide a specific option such as clozapine or a long-acting injectable, is a question to ask on the free discovery call. People who need clozapine monitoring, injections or a coordinated specialty care program are often best served by a clinic that provides those services directly. For other decisions about care, see the guide to choosing psychiatric care.

Frequently asked questions

Is clozapine still hard to get after the REMS was removed?

FDA removed the clozapine REMS effective June 13, 2025, so prescribers, pharmacies and patients no longer enroll in a federal program. Regular blood monitoring is still recommended in the prescribing information, so you will still need lab visits.

Does Cobenfy cause weight gain?

Its most common side effects in trials were gastrointestinal, along with raised heart rate and dizziness. Ask your prescriber how its metabolic profile compares with your current medicine; long-term comparative data are still limited.

Are long-acting injectables only for people who do not take their pills?

No. The APA guideline suggests them for people who prefer them as well as for those with poor or uncertain adherence. Many people choose them for convenience.

Are first-generation antipsychotics worse than second-generation ones?

Not uniformly. Large analyses show gradual efficacy differences across drugs and bigger differences in side effects, which vary within each generation. The choice depends on the individual's risks and priorities.

Can antipsychotics be stopped once symptoms are gone?

The APA guideline recommends continuing antipsychotic treatment in people whose symptoms have improved. Any change should be planned with the prescriber; stopping on your own raises the risk of relapse.

What if two antipsychotics have not worked?

Confirm that both trials were at an adequate dose and duration and that the medicine was taken. If adequate trials of at least two different antipsychotics have not helped, NICE guidance recommends offering clozapine, so this is the point to discuss it with the prescriber.

Sources

1. APA Releases New Practice Guideline on Treatment of Patients with Schizophrenia. American Psychiatric Association, 2020. psychiatry.org
2. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939-951 (Huhn et al.), 2019. pubmed.ncbi.nlm.nih.gov
3. Clozaril (clozapine) prescribing information. HLS Therapeutics / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
4. FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug Clozapine. U.S. Food and Drug Administration, Drug Safety Communication, 2025. fda.gov
5. FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia. U.S. Food and Drug Administration, news release, 2024. fda.gov
6. Cobenfy (xanomeline and trospium chloride) prescribing information. Bristol Myers Squibb (E.R. Squibb & Sons) / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
7. Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia. Bristol Myers Squibb (press release), 2025. news.bms.com
8. Invega Sustenna (paliperidone palmitate) prescribing information. Janssen Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
9. Abilify Maintena (aripiprazole) prescribing information. Otsuka America Pharmaceutical / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
10. Zyprexa Relprevv (olanzapine pamoate) prescribing information. H2-Pharma / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
11. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 8(5):387-404 (Kishimoto et al.), 2021. pubmed.ncbi.nlm.nih.gov
12. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia: A Nationwide Study With 20-Year Follow-up. Schizophrenia Bulletin 44(6):1381-1387 (Taipale et al.), 2018. pubmed.ncbi.nlm.nih.gov
13. The place of long-acting injectable antipsychotics in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology (Kane & Rubio), 2023. pmc.ncbi.nlm.nih.gov
14. Psychosis and schizophrenia in adults: prevention and management (CG178), Recommendations. National Institute for Health and Care Excellence (NICE), 2014. nice.org.uk

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.